

01

Strong growth continued for middle market life sciences companies, but their outlook dims

While middle market life sciences companies maintained doubledigit growth in the first half of 2023, their optimism is fading

- Almost half following boom times for this sector from the pandemic, mean revenue growth cooled slightly, but is expected to decline significantly over the next year to about half its actual level at the end of 2022
- After hitting a pandemic-era high at yearend, mean employment growth dropped in the first half – but remained above the mid-2022 reading – and is expected to fall further in the coming year
- Far fewer companies noted that their performance improved in the past 12 months, compared to the mid-2022 survey

Economic confidence declined

- Confidence in the global, national and local economies dropped below their levels of a year ago
- Global and national economic confidence fell significantly after spiking at year-end

Views on expansion opportunities align with dimmer outlook

 While the pandemic provided these companies many opportunities to introduce innovative products and solutions and grow their geographic footprint, all of the top areas that that they plan to expand in the coming year are lower than a year ago – some sharply

Artificial intelligence (AI) and the bank failure crisis were prominent in business headlines

- While AI technology is still in its early stages, more than two-thirds of middle market life sciences companies recognize it as critical to their organization and threequarters are taking some action to adopt new technologies like AI
- Three-quarters of companies showed a significant level of concern from the banking crisis, prompting a third or more to either split money across different banks or purchased more FDIC coverage

THE DATA BEHIND THE FINDINGS

Growth begins slowing

Mean revenue growth

15.1% 2022 (Q2) 15.1% 13.8%

Projection (next 12 months): 7.9%

 $48\% \ \ \text{of companies expect to} \\ \text{increase revenue}$

Mean employment growth

14.5% 2023 (Q2) 15.5%

Projection (next 12 months): 12.7%

 $52\% \begin{array}{l} \text{of companies expect to} \\ \text{increase employment} \end{array}$

Companies improving their performance over the past year

2022 (Q2) 90% 66%

Confidence in the economy

Global economy

2023 (Q2): **84%**

2022 (Q2): **90%**

National economy

2023 (Q2): **83%**

2022 (Q2): 92%

Local economy

2023 (Q2): **88%**

2022 (Q2): 92%

Expansion plans in next year

Introduce a new product or service

 $66\% \quad \textbf{-9} \text{ from Q2 2022}$

Expand into new international markets

64% -1 from Q2 2022

Bring in new equity investment

53% -**14** from Q2 2022

Expand into new domestic markets

59%

-20 from O2 2022

Trending topic

Artificial intelligence (AI)

Importance to organization

69% extremely/very

Adoption levels

• 31% testing/using

• 45% exploring/trying it out

Level of concern 75% a lot/some

Top responses

• 41% split money across different banks

• 33% purchase additional FDIC coverage

Top business concerns shift for Middle Market life sciences companies

As supply chain fears faded, workforce and recession ranked as most concerning for these companies

- Most life sciences companies are challenged by finding employees with the right skills and nearly all note that digital skills will be crucial to their success in the next few years
- As a result of these talent shortage and hiring issues, more than two in five companies are continuing to have employees work longer hours or more shifts

Recession concerns have increased

- Although a potential recession has become more of a concern to middle market life sciences companies, they believe they would experience a net positive impact from it
- As these companies contemplate a recession scenario, their response strategies would center around raising capital, conserving cash, and delaying the introduction of new products or services


Supply chain concerns eased

• After peaking at year-end, middle market life sciences companies' concerns about supply chain issues and difficulty managing them receded significantly in the first half of 2023

THE DATA BEHIND THE FINDINGS

Biggest concerns facing middle market life sciences companies

- Workforce 23%
 - Recession 16%
- Supply chain 15%
- Geopolitical instability 15%
- Inflation 13%
- Catastrophic incidents 11%
- Access to capital 7%



Views on potential recession

Positive impact

Negative impact

30%

Top expected responses to a recession

Raise capital

Conserve cash

Delay introducing a new product/service

Cut expenses via budget reductions

Addressing workforce challenges

Challenged* by finding/hiring employees with the right skills

*extremely/very challenged/somewhat challenged

Talent with digital skills will be critical/important to our success in next two to three years

Employees working longer hours/more shifts due to talent/hiring issues

Risk management challenges reflect top business concerns

Talent and public health concerns led risk management challenges for middle market life sciences companies

Life sciences companies are finding it harder to hire and retain employees, making it their top risk management challenge. Additionally, workforce is top of mind as these companies consider their insurance purchasing decisions.

Cybersecurity is also a key factor in their insurance strategies. Cyber disruptions caused major revenue impacts for life sciences companies, and more than half that experienced these disruptions acknowledged that they could have been covered for them if they had purchased available insurance. Understanding potential cyber threats, taking steps to reduce them, and if necessary, transferring risk through insurance, can help companies avoid or recover from a cyber event.

Internet of Things (IoT) capabilities offer solutions for managing key risks

Additionally, infrastructure and oftenrelated catastrophic incident concerns weigh into insurance purchasing decisions for about half of these companies. Increases in frequency, severity, and diversity of severe weather and natural catastrophes caused by climate change – including wildfires, drought/heat waves, tornadoes, hurricanes, and flooding – all have an impact on operations and the bottom line.

Companies can benefit from IoT solutions, such as water shutoff valves, and life sciences companies in particular can minimize such risks as temperature control and product contamination by taking advantage of Chubb's risk assessment expertise that emphasizes business continuity planning.

This dynamic risk environment makes it critical for middle market companies to review the adequacy of their insurance coverage and risk mitigation programs with their insurance agents and brokers.

THE DATA BEHIND THE FINDINGS

Companies finding risks extremely/very challenging to manage

Talent shortage/employee retention*

2023 (Q2): **56%**

Increasing public health concerns targeting common products and processes*

2023 (Q2): **52%**

Inflation

2023 (Q2): **51%**

2022 (Q2): **58%**

Competitive risk

2023 (Q2): **51%**

2022 (O2): 58%

*New response choice in Q2 2023

Concerns factoring into insurance purchasing decisions

(sum of 1st, 2nd and 3rd concern rankings)

- 61% Workforce
- 60% Cybersecurity
- 52% Infrastructure
- 47% Catastrophic incidents (not cyber) or in some cases, natural disasters

Role of insurance in disruptions

82%

experienced non-pandemic business disruptions in the past two years

Key losses covered or could have been:

Cyber disruption

Covered

31%

Coverage available but not purchased

52%

39% mean negative revenue impact from cyber disruptions

Operational disruption

Covered

55%

Coverage available but not purchased

26%

RESOURCES TO STAY UP TO DATE ON KEY RISKS

Insurance for Life Sciences Companies

Cyber Insurance

Economic Forces Impact Commercial Property Replacement Costs

The Impact of Climate Change

Natural Hazards and Climate Change Preparedness Physical Risk Assessment

<u>Using IoT Water Sensors to Protect the Vital Work of Life Sciences Companies</u>

More than ever, Middle Market companies need expert advice on how to manage evolving risks



Chubb, along with its agent and broker partners, can provide insights on the exposures surrounding these risks, as well as specialized risk engineering services to evaluate and mitigate exposures. Additionally, Chubb can offer solutions for managing these risks through customized insurance coverages that provide essential protection.

For more information about these or other topics, visit chubb.com.

Statistical data contained herein is provided by the National Center for the Middle Market unless otherwise stated. The material presented herein is not intende to provide legal or other expert advice as to any of the subjects mentioned, but rather is presented for general information only. You should consult knowledgeab experts as to any legal or technical questions you may have. Chubb is the marketing name used to refer to subsidiaries of Chubb Limited providing insurance and related services. For a list of these subsidiaries, please wist our website at www.chubb.com. Insurance provided by ACE American Insurance Company and its USA based Chubb with a conderviring company affiliates. All products may not be available in all states. Coverage is subject to the language of the policies as actually issued.